JP2014531442A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531442A5
JP2014531442A5 JP2014530369A JP2014530369A JP2014531442A5 JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5 JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014530369 A JP2014530369 A JP 2014530369A JP 2014531442 A5 JP2014531442 A5 JP 2014531442A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
polypeptide
coli
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531442A (ja
Filing date
Publication date
Priority claimed from GB201115906A external-priority patent/GB201115906D0/en
Priority claimed from GBGB1213251.0A external-priority patent/GB201213251D0/en
Application filed filed Critical
Priority claimed from PCT/IB2012/054825 external-priority patent/WO2013038385A2/en
Publication of JP2014531442A publication Critical patent/JP2014531442A/ja
Publication of JP2014531442A5 publication Critical patent/JP2014531442A5/ja
Pending legal-status Critical Current

Links

JP2014530369A 2011-09-14 2012-09-14 Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ Pending JP2014531442A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201115906A GB201115906D0 (en) 2011-09-14 2011-09-14 Escherichia coli vaccine combination
GB1115906.8 2011-09-14
GBGB1213251.0A GB201213251D0 (en) 2012-07-25 2012-07-25 Escherichia coli vaccine combination
GB1213251.0 2012-07-25
PCT/IB2012/054825 WO2013038385A2 (en) 2011-09-14 2012-09-14 Escherichia coli vaccine combination

Publications (2)

Publication Number Publication Date
JP2014531442A JP2014531442A (ja) 2014-11-27
JP2014531442A5 true JP2014531442A5 (cg-RX-API-DMAC7.html) 2015-10-15

Family

ID=47116137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530369A Pending JP2014531442A (ja) 2011-09-14 2012-09-14 Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ

Country Status (5)

Country Link
US (2) US9511130B2 (cg-RX-API-DMAC7.html)
EP (1) EP2755994A2 (cg-RX-API-DMAC7.html)
JP (1) JP2014531442A (cg-RX-API-DMAC7.html)
CN (1) CN103930436A (cg-RX-API-DMAC7.html)
WO (1) WO2013038385A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN109234418B (zh) * 2018-11-20 2021-08-13 湖南中净生物科技有限公司 一种鉴别猪肺炎支原体野毒株和疫苗株的引物、试剂盒和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
JP2004529906A (ja) 2001-03-19 2004-09-30 イオマイ コーポレイシヨン 経皮的免疫賦活
EP1383918A4 (en) 2001-04-03 2005-01-05 Biosynexus Inc ANIMAL MODEL FOR DARMPATHOGENE
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20070128183A1 (en) 2004-04-27 2007-06-07 Intercell Ag Td antigens
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
AU2010272243A1 (en) * 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins

Similar Documents

Publication Publication Date Title
JP2015517489A5 (cg-RX-API-DMAC7.html)
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
CN106456723B (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
JP2016539946A5 (cg-RX-API-DMAC7.html)
JP2013534532A5 (cg-RX-API-DMAC7.html)
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
JP2015522576A5 (cg-RX-API-DMAC7.html)
JP2012525128A5 (cg-RX-API-DMAC7.html)
US9169477B2 (en) Compositions and methods for immunization against bacteria expressing a carbapenemase
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2015500827A5 (cg-RX-API-DMAC7.html)
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
JP2016504993A5 (cg-RX-API-DMAC7.html)
JP2013523718A5 (cg-RX-API-DMAC7.html)
Menheniott et al. STAT3: a critical component in the response to Helicobacter pylori infection
JP2018529661A5 (cg-RX-API-DMAC7.html)
WO2014145357A2 (en) Improved methods of use for recombinant human secretoglobins
JP2009519025A5 (cg-RX-API-DMAC7.html)
US8741302B2 (en) Polypeptide derived from Enterococcus and its use for vaccination
CN106380510B (zh) 鲍式不动杆菌的新靶标
JP2019526261A5 (cg-RX-API-DMAC7.html)
JP2014531442A5 (cg-RX-API-DMAC7.html)
JP2019531100A5 (cg-RX-API-DMAC7.html)